한글목차

COVID-19 감염증 치료제 관련 API 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 71억 4,000만 달러에서 2026년에는 75억 5,000만 달러로, CAGR 5.8%로 확대될 것으로 예상됩니다. 지난 수년간의 성장은 COVID-19 확진자 급증, 기존 의약품의 전환 수요의 긴급성, 항바이러스 APIS 공급 제한, 아시아태평양 수입 의존도, 긴급 승인 가속화 등이 요인으로 분석됩니다.

COVID-19 감염증 치료제 관련 API 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 96억 9,000만 달러에 달하고, CAGR은 6.4%가 될 전망입니다. 예측 기간의 성장 요인으로는 차세대 항바이러스제 및 면역조절제 개발, 국내 API 제조 확대, 생명공학 합성 기술 도입 증가, 팬데믹 대응을 위한 정부 자금 증가, 다양한 COVID-19 치료제에 대한 수요 증가 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 항바이러스제 및 항말라리아제 API에 대한 수요 증가, 자체 API 생산 및 외부 조달 API 생산에 대한 관심 증가, 합성 및 생명공학 기반 API 생산 확대, COVID-19 치료제 R&D 투자 증가, API 품질 및 공급망에 대한 규제 모니터링 강화 등이 있습니다.에 대한 규제 감시 강화 등을 들 수 있습니다.

정부 주도의 헬스케어 분야 연구개발 지원 정책은 향후 몇 년간 COVID-19 관련 원료의약품(API) 시장의 성장을 견인할 것으로 예상됩니다. 정부 주도의 이니셔티브는 특정 과제를 해결하고 명확한 목표를 달성하기 위해 지방, 지역, 국가 또는 국제 수준에서 시행되는 특정 대상의 시책, 프로그램, 정책 또는 프로젝트를 말합니다. 정부가 혁신을 촉진하고 공중보건의 중요한 요구에 대응하는 새로운 치료법을 빠르게 발견하기 위해 헬스케어 분야의 연구개발에 대한 투자를 늘리고 있습니다. COVID-19 치료제 관련 API는 COVID-19 치료제 및 백신의 신속한 개발, 시험, 대규모 생산에 필요한 필수 유효성분을 공급함으로써 이러한 노력을 뒷받침하고 있습니다. 예를 들어, 영국 통계청(ONS)에 따르면, 2025년 4월 기준 정부의 R&D 순지출은 2023년 174억 파운드(201억 달러)로 2022년 161억 파운드에서 증가하였다고 합니다. 따라서 헬스케어 연구개발에 대한 정부의 노력이 증가하면서 COVID-19 관련 의약품 API 시장의 성장에 기여하고 있습니다.

신종 코로나바이러스 감염증 치료제 관련 원료의약품 시장에서 사업을 영위하는 주요 기업들은 경쟁 우위를 강화하기 위해 경구용 COVID-19 치료제 등 혁신적 제품 출시에 집중하고 있습니다. 경구용 COVID-19 치료제는 SARS-CoV-2 바이러스에 의한 감염증을 치료하기 위해 경구 투여하는 의약품입니다. 예를 들어, 2023년 5월 미국 제약회사 화이자가 미국 식품의약국(FDA)의 승인을 받아 'PAXLOVID'를 출시했습니다. 이 경구용 시험 치료제(SARS-CoV-2 프로테아제 억제제)는 COVID-19에 감염된 입원하지 않은 고위험군 성인에서 위약 대비 입원 또는 사망 위험을 89% 감소시키는 효과가 확인되었습니다. 이 치료제는 증상 발현 초기 또는 감염이 확인된 시점에 조기 사용을 목적으로 하며, 중증화, 입원, 사망 예방에 기여할 수 있도록 설계되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

COVID-19 drug-associated APIs refer to the active pharmaceutical ingredients used in the manufacture of medications for the treatment of COVID-19. Active pharmaceutical ingredients are chemical substances that form the core of pharmaceutical drugs and are responsible for their pharmacological effects in the human body.

The primary classes of drugs in COVID-19 drug-associated APIs include antimalarials, bronchodilators, antibiotics, antivirals, and others. Antimalarial drugs are antiparasitic chemical agents used to treat or prevent malaria and are generally derived from organic sources. These APIs are available in both generic and branded forms and are produced through different business models such as captive API manufacturing and merchant API production.

Tariffs have influenced the COVID-19 drug-associated APIs market by increasing the cost of imported raw materials, active pharmaceutical ingredients, and precursors required for antiviral, antimalarial, and antibiotic drugs. Segments such as synthetic APIs and captive API manufacturing are most affected, with North America, Europe, and Asia-Pacific regions facing significant import duties. While tariffs have increased production costs and caused supply chain disruptions, they have also incentivized local API manufacturing, innovation in synthetic and biotech production, and long-term diversification of the supply base.

The covid-19 drug associated apis market research report is one of a series of new reports from The Business Research Company that provides covid-19 drug associated apis market statistics, including covid-19 drug associated apis industry global market size, regional shares, competitors with a covid-19 drug associated apis market share, detailed covid-19 drug associated apis market segments, market trends and opportunities, and any further data you may need to thrive in the covid-19 drug associated apis industry. This covid-19 drug associated apis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The covid-19 drug associated apis market size has grown strongly in recent years. It will grow from $7.14 billion in 2025 to $7.55 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to initial surge in covid-19 cases, urgent need for repurposed drugs, limited availability of antiviral apis, dependency on imports from asia-pacific, accelerated emergency approvals.

The covid-19 drug associated apis market size is expected to see strong growth in the next few years. It will grow to $9.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to development of next-generation antiviral and immunomodulator apis, expansion of domestic api manufacturing, increasing adoption of biotech synthesis, rising government funding for pandemic preparedness, growing demand for diversified covid-19 treatment options. Major trends in the forecast period include rising demand for antiviral and antimalarial apis, increased focus on captive and merchant api manufacturing, expansion of synthetic and biotech-based api production, growing investment in research and development for covid-19 drugs, enhanced regulatory oversight on api quality and supply chains.

Government initiatives supporting research and development in healthcare are expected to drive the growth of the COVID-19 drug-associated active pharmaceutical ingredient (API) market in the coming years. Government initiatives include targeted actions, programs, policies, or projects implemented at local, regional, national, or international levels to address specific challenges and achieve defined objectives. Investment in healthcare research and development is increasing as governments aim to stimulate innovation and accelerate the discovery of new therapies that address critical public health needs. COVID-19 drug-associated APIs support these initiatives by supplying essential active ingredients required for the rapid development, testing, and large-scale production of COVID-19 treatments and vaccines. For example, in April 2025, according to the Office for National Statistics, a UK government agency, government net expenditure on research and development reached £17.4 billion ($20.10 billion) in 2023, up from £16.1 billion in 2022. Therefore, increasing government initiatives for healthcare research and development are contributing to the growth of the COVID-19 drug-associated API market.

Major companies operating in the COVID-19 drug-associated API market are increasingly focusing on the launch of innovative products, such as oral COVID-19 treatments, to strengthen their competitive position. Oral COVID-19 treatments are medications administered by mouth to treat infections caused by the SARS-CoV-2 virus. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company, launched PAXLOVID following approval by the U.S. Food and Drug Administration. This oral investigational therapy, a SARS-CoV-2 protease inhibitor, demonstrated an 89% reduction in the risk of hospitalization or death compared with placebo in high-risk, non-hospitalized adults with COVID-19. Intended for early use at the onset of symptoms or upon known exposure, the treatment is designed to help prevent severe disease, hospitalization, and mortality.

In January 2023, Sterling Pharma Solutions, a US-based pharmaceutical company, acquired an active pharmaceutical ingredient manufacturing facility from Novartis AG for an undisclosed amount. Through this acquisition, Sterling expanded its API manufacturing capacity, and the accompanying long-term supply agreement with Novartis enables continued production of several APIs used in cardiovascular, immunology, and oncology therapies. Novartis AG is a global pharmaceutical company involved in the manufacture of active pharmaceutical ingredients.

Major companies operating in the covid-19 drug associated apis market are Dr. Reddy's Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd.

North America was the largest region in the COVID-19 drug-associated APIs market in 2025. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated APIs market share during the forecast period. The regions covered in the covid-19 drug associated apis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the covid-19 drug associated apis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The COVID-19 drug-associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

COVID-19 Drug Associated APIs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses covid-19 drug associated apis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for covid-19 drug associated apis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The covid-19 drug associated apis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Antimalarials; Bronchodilators; Antibiotics; Antivirals; Other Drug Class
• 2) By Synthesis Type: Synthetic; Biotech
• 3) By Business Mode: Captive API; Merchant API
• Subsegments:
• 1) By Antimalarials: Hydroxychloroquine; Chloroquine
• 2) By Bronchodilators: Beta-Agonists; Anticholinergics
• 3) By Antibiotics: Macrolides; Tetracyclines
• 4) By Antivirals: Remdesivir; Favipiravir; Lopinavir Or Ritonavir
• 5) By Other Drug Classes: Corticosteroids; Immunomodulators
• Companies Mentioned: Dr. Reddy's Laboratories Ltd.; Lianyungang Guike Pharmaceutical CO. LTD.; Alembic Pharmaceuticals Ltd.; Wockhardt Ltd.; Sandoz Srl; Lupin Limited; Aurobindo Pharma Ltd.; Shanghai Shyndec Pharmaceutical Co. Ltd.; Zhejiang Yatai Pharmaceutical Co. Ltd.; Zhejiang Guobang Pharmaceutical Co Ltd.; Cipla Limited; Shandong Boyuan Pharmaceutical Co. Ltd.; Aspiro Pharma Ltd.; Qilu Antibiotics Pharmaceutical Co. Ltd.; Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd.; Zhejiang Cheng Yi Pharmaceutical; Star Lake Bioscience Co.Inc.; Hetero Labs Ltd.; Geno Pharmaceuticals Ltd.; Mylan Laboratories Ltd.; Ipca Laboratories Limited; Zydus Takeda Healthcare Private Limited; Mangalam Drugs & Organics; Wallace Pharmaceuticals; Zhejiang Hisun Pharmaceutical Co. Ltd.; Zhejiang Huahai Pharmaceutical Co. Ltd.; Zhejiang Jiuzhou Pharmaceutical Co. Ltd.; Zhejiang NHU Co. Ltd.; Zhejiang Xianju Pharmaceutical Co. Ltd.; Zhejiang Yongtai Technology Co. Ltd.; Zhejiang Zhebei Pharmaceutical Co. Ltd.; Zhejiang Tianyu Pharmaceutical Co. Ltd.; Zhejiang Aisheng Pharmaceutical Co. Ltd.; Zhejiang Aokang Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. COVID-19 Drug Associated APIs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global COVID-19 Drug Associated APIs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. COVID-19 Drug Associated APIs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global COVID-19 Drug Associated APIs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Demand For Antiviral And Antimalarial Apis
  • 4.2.2 Increased Focus On Captive And Merchant Api Manufacturing
  • 4.2.3 Expansion Of Synthetic And Biotech-Based Api Production
  • 4.2.4 Growing Investment In Research And Development For Covid-19 Drugs
  • 4.2.5 Enhanced Regulatory Oversight On Api Quality And Supply Chains

5. COVID-19 Drug Associated APIs Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biotech Firms
• 5.3 Hospitals
• 5.4 Contract Research Organizations (Cros)
• 5.5 Government Health Agencies

6. COVID-19 Drug Associated APIs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global COVID-19 Drug Associated APIs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global COVID-19 Drug Associated APIs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global COVID-19 Drug Associated APIs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global COVID-19 Drug Associated APIs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global COVID-19 Drug Associated APIs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global COVID-19 Drug Associated APIs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. COVID-19 Drug Associated APIs Market Segmentation

• 9.1. Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class
• 9.2. Global COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Synthetic, Biotech
• 9.3. Global COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Captive API, Merchant API
• 9.4. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Antimalarials, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hydroxychloroquine, Chloroquine
• 9.5. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Bronchodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Beta-Agonists, Anticholinergics
• 9.6. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Macrolides, Tetracyclines
• 9.7. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Remdesivir, Favipiravir, Lopinavir Or Ritonavir
• 9.8. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Corticosteroids, Immunomodulators

10. COVID-19 Drug Associated APIs Market Regional And Country Analysis

• 10.1. Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific COVID-19 Drug Associated APIs Market

• 11.1. Asia-Pacific COVID-19 Drug Associated APIs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China COVID-19 Drug Associated APIs Market

• 12.1. China COVID-19 Drug Associated APIs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India COVID-19 Drug Associated APIs Market

• 13.1. India COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan COVID-19 Drug Associated APIs Market

• 14.1. Japan COVID-19 Drug Associated APIs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia COVID-19 Drug Associated APIs Market

• 15.1. Australia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia COVID-19 Drug Associated APIs Market

• 16.1. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea COVID-19 Drug Associated APIs Market

• 17.1. South Korea COVID-19 Drug Associated APIs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan COVID-19 Drug Associated APIs Market

• 18.1. Taiwan COVID-19 Drug Associated APIs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia COVID-19 Drug Associated APIs Market

• 19.1. South East Asia COVID-19 Drug Associated APIs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe COVID-19 Drug Associated APIs Market

• 20.1. Western Europe COVID-19 Drug Associated APIs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK COVID-19 Drug Associated APIs Market

• 21.1. UK COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany COVID-19 Drug Associated APIs Market

• 22.1. Germany COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France COVID-19 Drug Associated APIs Market

• 23.1. France COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy COVID-19 Drug Associated APIs Market

• 24.1. Italy COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain COVID-19 Drug Associated APIs Market

• 25.1. Spain COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe COVID-19 Drug Associated APIs Market

• 26.1. Eastern Europe COVID-19 Drug Associated APIs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia COVID-19 Drug Associated APIs Market

• 27.1. Russia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America COVID-19 Drug Associated APIs Market

• 28.1. North America COVID-19 Drug Associated APIs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA COVID-19 Drug Associated APIs Market

• 29.1. USA COVID-19 Drug Associated APIs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada COVID-19 Drug Associated APIs Market

• 30.1. Canada COVID-19 Drug Associated APIs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America COVID-19 Drug Associated APIs Market

• 31.1. South America COVID-19 Drug Associated APIs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil COVID-19 Drug Associated APIs Market

• 32.1. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East COVID-19 Drug Associated APIs Market

• 33.1. Middle East COVID-19 Drug Associated APIs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa COVID-19 Drug Associated APIs Market

• 34.1. Africa COVID-19 Drug Associated APIs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Segmentation By Synthesis Type, Segmentation By Business Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. COVID-19 Drug Associated APIs Market Regulatory and Investment Landscape

36. COVID-19 Drug Associated APIs Market Competitive Landscape And Company Profiles

• 36.1. COVID-19 Drug Associated APIs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. COVID-19 Drug Associated APIs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. COVID-19 Drug Associated APIs Market Company Profiles
  • 36.3.1. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Lianyungang Guike Pharmaceutical CO. LTD. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Alembic Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Wockhardt Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sandoz Srl Overview, Products and Services, Strategy and Financial Analysis

37. COVID-19 Drug Associated APIs Market Other Major And Innovative Companies

• Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd.

38. Global COVID-19 Drug Associated APIs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The COVID-19 Drug Associated APIs Market

40. COVID-19 Drug Associated APIs Market High Potential Countries, Segments and Strategies

• 40.1 COVID-19 Drug Associated APIs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 COVID-19 Drug Associated APIs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 COVID-19 Drug Associated APIs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer